Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
RR 0.97 [0.67, 1.42]
965 participants
Low
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower total cardiovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower cerebrovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in coronary heart disease mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Decrease in SBP5 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Decrease in DBP6 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Sudden cardiac death · patients with hypertension
Antihypertensive pharmacotherapy showed no clear difference in sudden cardiac death ( compared with control (moderate certainty).
1 finding from 1 review
Non‐fatal MI · patients with hypertension
Antihypertensive pharmacotherapy probably leads to lower non‐fatal myocardial infarction ( compared with control (moderate certainty).
1 finding from 1 review
Fatal myocardial infarction ( · patients with hypertension
Antihypertensive pharmacotherapy probably leads to lower fatal myocardial infarction ( compared with control (moderate certainty).
1 finding from 1 review
Residual kidney function (24 months) · patients receiving PD
1 finding from 1 review
Residual kidney function (12 months) · patients receiving PD
1 finding from 1 review
Anuria · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
1 finding from 1 review